For the Inventor, By the Inventor

Enter assignee name

Harrison, NY, United States of America

Shy Therapeutics LLC

Calculating rank

USPTO Granted Patents = 13

EPO Patents = 2

Forward Citations = 25

Loading Chart...

Loading Chart...

8 inventors (with patents filed for the assignee):

Yaron R Hadari (13 out of 24 patents)

Luca Carta (13 out of 14 patents)

Theresa M Williams (13 out of 61 patents)

4. Michael Schmertzler (13 out of 18 patents)

5. Charles Howard Reynolds (13 out of 50 patents)

6. Rebecca Hutcheson (10 out of 10 patents)

7. Carolina Bigarella (1 out of 1 patent)

8. Sufang Zhang (1 out of 1 patent)

13 patents: Sort by Forward Citations

1. 12653810 - Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease (2026-06-16),

2. 12459951 - Compounds that interact with RAS superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease (2025-11-04),

3. 12391705 - Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease (2025-08-19),

4. 12168668 - Compounds for the treatment of cancer and inflammatory disease (2024-12-17),

5. 11560390 - Compounds for the treatment of cancer and inflammatory disease (2023-01-24),

6. 11541041 - Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease (2023-01-03),

7. 11213515 - Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease (2022-01-04),

8. 11026930 - Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease (2021-06-08),

9. 11000515 - Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease (2021-05-11),

10. 10940139 - Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease (2021-03-09),

11. 10933054 - Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease (2021-03-02),

12. 10870657 - Compounds for the treatment of cancer and inflammatory disease (2020-12-22),

13. 10588894 - Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease (2020-03-17),

Company Overview

Shy Therapeutics LLC, based in Harrison, NY, specializes in developing innovative therapeutic solutions aimed at addressing unmet medical needs. The company focuses on advancing drug delivery technologies and enhancing treatment efficacy through its proprietary platforms. By leveraging cutting-edge research in pharmacology and biochemistry, Shy Therapeutics aims to improve patient outcomes and streamline therapeutic processes. Its commitment to scientific excellence positions it as a key player in the biopharmaceutical landscape.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

13 Patents

#3 in Harrison, NY

#1,380 in New York

#23,878 in US

#45,137 in the World

Harrison, NY, United States of America

Shy Therapeutics LLC

Forward Citations = 25

8 inventors:

Yaron R Hadari (13 out of 24 patents)

Luca Carta (13 out of 14 patents)

Theresa M Williams (13 out of 61 patents)

4. Michael Schmertzler (13 out of 18 patents)

5. Charles Howard Reynolds (13 out of 50 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Shy Therapeutics LLC. Retrieved from https://idiyas.com/company/shy-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…